What is AIM Laboratories?
AIM Laboratories operates as a specialized molecular diagnostic laboratory, offering an extensive suite of testing services. Their expertise spans PCR testing for various infectious agents including Covid-19, antibiotic resistance, and respiratory infections, alongside pharmacogenomics, women's health, and wound diagnostics. The laboratory is committed to delivering rapid turnaround times and high-quality results to healthcare providers and corporate clients across the United States, leveraging advanced technology and robust customer support to enhance patient care. Their comprehensive test menu also includes complex chemistry, toxicology, and clinical endocrinology services.
How much funding has AIM Laboratories raised?
AIM Laboratories has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in AIM Laboratories
PPP
Public-Private Partnership
What's next for AIM Laboratories?
With its large-scale late-stage funding, AIM Laboratories is poised for significant expansion and operational enhancement. The recent strategic investment likely signals a focus on scaling its service offerings, potentially through technological advancements, broader market penetration, or strategic partnerships. This capital infusion will be critical in solidifying its position as a leading provider of molecular diagnostic solutions, enabling the company to meet the growing demand for accurate and timely health assessments. Future developments may include expanding its testing portfolio or enhancing its laboratory infrastructure to support increased volume and complexity of diagnostic services.
See full AIM Laboratories company page
